Linderalactone mitigates diabetic renal injury by inhibiting macrophage inflammation via the Dectin1/Syk/ <scp>CARD9</scp> / <scp>IRF5</scp> / <scp>NF</scp> ‐ <scp>κB</scp> pathway
LNL alleviates DN via suppression of macrophage inflammation by mediating the Dectin1/Syk/CARD9/IRF5/NF-κB signaling pathway, highlighting its potential as a therapeutic agent for diabetes-associated renal injury.
Authors
- Huishang Wang
- Sheng Xu (ORCID: https://orcid.org/0000-0001-5123-0592)
- Hao Chen
- Tianrui Wang
- Jinrui Hu
- Yuhong Wu
- Bingrong Chen
- Xishan Xiong
Institutions
- Zigong First People's Hospital (CN)
- Anyang Hospital of Traditional Chinese Medicine (CN)
Publication Details
- Journal
- Journal of Diabetes Investigation
- Published
- 2026-01-08
- DOI
- https://doi.org/10.1111/jdi.70222
- Primary Topic
- Chronic Kidney Disease and Diabetes
- Type
- article
- Field-Weighted Citation Impact
- 0.00